Cardlytics, Inc. reported impairment charges for the fourth quarter ended December 31, 2023. For the quarter, the company reported impairment of goodwill and intangible assets of $70,518,000 against $370,139,000 a year ago.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
8.85 USD | -4.53% | -40.96% | -4.61% |
05-09 | Craig-Hallum Adjusts Cardlytics Price Target to $12 From $18, Maintains Buy Rating | MT |
05-09 | Needham Adjusts Price Target on Cardlytics to $12 From $17, Keeps Buy Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-4.61% | 447M | |
+10.39% | 3,064B | |
+8.22% | 83.88B | |
+5.60% | 77.63B | |
-13.73% | 53.97B | |
+20.24% | 47.08B | |
-24.40% | 46.81B | |
+21.43% | 43.34B | |
+60.43% | 37.9B | |
-9.29% | 24.85B |
- Stock Market
- Equities
- CDLX Stock
- News Cardlytics, Inc.
- Cardlytics, Inc. Reports Impairment Charges for the Fourth Quarter Ended December 31, 2023